Background A new beta 3-adrenoceptor (beta (3)-AR) has been shown to mediat
e peripheral vasodilation. This study was conducted to evaluate effects of
the beta (3)-AR agonist, SR58611 in normal and hypertensive dogs.
Materials and Methods In protocol 1, SR58611 was infused in normal dogs aft
er placebo, after beta1/beta2 blockade with nadolol, after beta1/beta2/beta
3 blockade with bupranolol and after combined autonomic blockade (CAB). In
protocol 2, perinephritic hypertension was produced in dogs, which received
SR58611 at 3 and 6 weeks of hypertension. Effects of SR58611 were evaluate
d at 7 weeks of hypertension after CAB.
Results In normal dogs, SR58611 produced a dose-dependent decrease in mean
aortic pressure (AOP) (from 116 +/- 19 to 100 +/- 19 mmHg, - 14%; P < 0.05)
that was accompanied by baroreflex activation (heart rate increased by 70%
; P < 0.01). This hypotensive effect resulting from peripheral vasodilation
persisted after nadolol or CAB while baroreflex activation was blunted or
abolished. A biphasic response of cardiac output, characterized by a rise a
nd a decline (P < 0.05) reflected a reduction in after- and pre-load. After
CAB, SR58611 did not modify cardiac contractility. SR58611 stimulated lipo
lysis as reflected by a 4-fold increase in blood free fatty acids (FFA) (P
< 0.0005). Under CAB, the rise of FFA was reduced (P < 0.01). In hypertensi
ve dogs, SR58611 produced a dose-dependent decrease in mean AOP (from 168 /- 32 to 125 +/- 35 mmHg; -26%, P < 0.0001), that was greater than in norma
l dogs (P < 0.05). Reflex-mediated tachycardia also occurred but at higher
blood pressure values. Blood FFA rose similarly (P < 0.0001). Under CAB, he
art rate remained unchanged but SR58611 still induced a decrease (P < 0.000
1) in mean AOP concomitantly with a rise of (dP/dt)/DP40 (P < 0.005), an ef
fect not observed in normal dogs.
Conclusions beta (3)-AR stimulation exerts hypotensive effects, increases c
ardiac contractility and stimulates lipolysis in hypertensive dogs.